Pulmonary Fibrosis Treatment Market 2022 Global Leading Companies Analysis, Revenue, Trends and Forecasts 2031|F. Hoffman, Cipla Ltd (Cipla) and more

Pulmonary Fibrosis Treatment Market 2022

The global Pulmonary Fibrosis Treatment Market is expected to go great guns in the next 10 years. It is slated to reach US$ 2.7 Bn by the year 2021. The CAGR would be 6.2%. With mixed reality in the foray, virtual objects could be integrated with the real-life ambience, thereby rendering simultaneous manipulation of digital twins. In other words, digital twinning is expected to be the future of healthcare vertical in the forecast period.

Monotherapy is cost-effective and gives deliverable action directly to the site of action in a few minutes, and is said to be a safe and effective method for treating idiopathic pulmonary fibrosis (IPF). According to Persistence Market Research (PMR), request for pulmonary fibrosis treatment is predicted to increase, enabling the market to surpass US$ 2.7 Bn by 2021. Over the coming years, rising cases of IPF will support expansion of the market.

Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/30070

High number of research & development projects, increasing investments, and favorable regulatory policies are some other factors supporting growth of the market for pulmonary fibrosis treatment. Majority of the population living with pulmonary fibrosis is being treated with traditional corticosteroid combination drugs with limited efficacy. With the arrival of new novel therapies, unaddressed populations in middle- and lower-income countries, as well as developed countries, can offer significant revenue generation opportunities.

Company Profiles:

F. Hoffman - La Roche Ltd.
Boehringer Ingelheim International GmbH
Cipla Ltd (Cipla)
Gilead Sciences, Inc.
Bristol-Myers Squibb Company
FibroGen Inc.
Galecto Inc

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/30070

Key Takeaways from Market Study

The global pulmonary fibrosis treatment market is expected to rise at a healthy CAGR over more than 6% through 2031.

Increasing focus on effective treatment in the U.S is lending high Y-o-Y growth to the market in the country.

Germany and France are expected to exhibit increasing demand to tackle concerns pertaining to rising incidence of IPF.

Overall, the global market is set to expand 2X over the next ten years.
Monotherapy to account for over 70% market share by 2031.

"Rising prevalence of idiopathic pulmonary fibrosis and importance of early diagnosis are creating growth opportunities for market players in the long term," says a Persistence Market Research analyst.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/30070

Collaborations and Product Approval - Imperative Strategy for Market Players

Leading market players are strengthening their market position through collaborations with various other organizations. Global leading companies are focusing on research activities and approvals for increased market penetration.

Roche, in March 2020, received Breakthrough Therapy Designation (BTD) from the U.S FDA for Esbriet (pirfenidone), for use in adults with unclassifiable interstitial lung disease (uILD).
In June 2019, Boehringer Ingelheim entered into a collaboration and license agreement with Bridge Biotherapeutics Inc. (South Korea), with the aim to fast-track the development of Bridge's auto tax in inhibitor BBT-877 for treatment against fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis, a rare lung disease.
In October 2020, Cipla introduced the generic version Nintedanib for the treatment of idiopathic pulmonary fibrosis. In India, this drug will be marketed under the brand name Ninitb. Nintedanib will be available in two formulations of 100 mg and 150 mg.

What else is in the report?

Persistence Market Research offers a unique perspective and actionable insights on the pulmonary fibrosis treatment market in its latest study, presenting historical demand assessment of 2016 - 2020 and projections for 2021 - 2031, based on therapy (monotherapy, combination therapy and symptomatic treatment), indication (idiopathic pulmonary fibrosis (IPF), familial PF, and others), and distribution channel (hospital pharmacies, retail pharmacies, and mail order pharmacies), across seven key regions of the world.

Access Related Reports-

Microsurgery Robot Market - https://www.persistencemarketresearch.com/market-research/microsurgery-robot-market.asp

Microsurgery robot market is anticipated to account for over US$ 1,562.9 Mn, in terms of value, by 2028 end.

 Arthroscopic Devices Market - https://www.persistencemarketresearch.com/market-research/arthroscopic-devices-market.asp

Global sales of arthroscopic devices will surpass the market value of US$ 10 Bn by the end of 2029.

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us: 

PersistenceMarketResearch is an esteemed company with a reputation of serving clients across domains of information technology (IT), healthcare, and chemicals. Our analysts undertake painstaking primary and secondary research to provide a seamless report with a 360 degree perspective. Data is compared against rep/uted organizations, trustworthy databases, and international surveys for producing impeccable reports backed with graphical and statistical information.

This release was published on openPR.